Publication: 3775

Publication: 3775

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.

PubMed

DOI

Google Scholar

Citation:: Ann Oncol vol 33 (4) 384-94

Year:: 2022
Type:: Manuscript
Funding:: AFT
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 11

Parents:: 3604
Children:: None

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:: AbbVie Inc.
Grants:

Corr. Author:
Authors:: C E Geyer W M Sikov J Huober H S Rugo N Wolmark J O'Shaughnessy D Maag M Untch M Golshan J Ponce Lorenzo O Metzger M Dunbar W F Symmans P Rastogi J H Sohn R Young G S Wright C Harkness K McIntyre D Yardley S Loibl

Networks:

Study: AFT-04
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: carboplatin, neoadjuvant chemotherapy, phase III, triple-negative breast cancer, veliparib